Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios Pro Rata

Dive into the world of dealmakers across VC, PE and M&A with Axios Pro Rata. Delivered daily to your inbox by Dan Primack and Kia Kokalitcheva.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Austin news?

Get a daily digest of the most important stories affecting your hometown with the Axios Austin newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Atlanta news?

Get a daily digest of the most important stories affecting your hometown with the Axios Atlanta newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Philadelphia news?

Get a daily digest of the most important stories affecting your hometown with the Axios Philadelphia newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Chicago news?

Get a daily digest of the most important stories affecting your hometown with the Axios Chicago newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top DC news?

Get a daily digest of the most important stories affecting your hometown with the Axios DC newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Shoshana Gordon/Axios

Democrats have agreed on a top-level deal that would allow Medicare to negotiate the prices of some drugs. But moderates and pharma allies successfully took some of the bite out of the party's preferred approach.

Why it matters: If the deal ultimately becomes law, Democrats will be able to claim victory on what's been a major priority for years, and many Americans struggling to afford their medication would receive relief.

The big picture: The deal hits on Democrats' three main pillars of drug price reform: It allows Medicare to negotiate the prices of some drugs, it puts a cap on how much drugmakers can hike prices in both Medicare and the commercial market, and it redesigns the Medicare Part D benefit in a way that significantly reduces seniors' out-of-pocket costs.

  • But negotiations are only allowed for a narrow subset of drugs, which will ultimately reduce the amount of government savings the bill achieves.
  • Experts say this approach will help blunt the bill's potential impact on drug companies' incentive to innovate on new drugs.

What they're saying: Key Democrats praised the deal yesterday, including Sens. Kyrsten Sinema, D-Ariz. and Bob Menendez, D-N.J., who had been concerned about the party taking an approach that was too aggressive.

  • Members who had wanted a more aggressive policy also put out statements of support.
  • "While not nearly as expansive as we had originally proposed, I'm hopeful the agreement's new inflation rebate and out-of-pocket cap for seniors will work in tandem with Medicare's negotiation authority to meaningfully lower prescription drug costs for Americans," House Energy and Commerce Chairman Frank Pallone, D-N.J., said in a statement.

The other side: PhRMA torched the watered-down plan.

  • "Under the guise of 'negotiation,' it gives the government the power to dictate how much a medicine is worth and leaves many patients facing a future with less access to medicines and fewer new treatments," said PhRMA CEO Stephen Ubl in a statement.

What happened: Democrats have scrambled behind closed doors since last week when the White House released a Build Back Better framework that didn't include prescription drug reforms.

  • After discussions between the White House and Sinema, House Speaker Nancy Pelosi and the White House ultimately decided not to include the version of Medicare negotiations that Sinema said she could support, according to sources familiar with the discussions.
  • In their view, Sinema's version was too weak. It would have allowed negotiations only in Part B — not Part D, which covers drugs at the pharmacy counter.
  • Negotiations continued over the weekend until a deal was reached yesterday.

What we're watching: A two-page outline is not legislative text, and the devil will be in the details as the party fleshes out its agreement.

The bottom line: "Democrats are taking an important step toward matching our policy walk with our collective multi-decade talk," said Democratic strategist Chris Jennings.

  • "While far from flawless, this legislation will place a check on excessive drug prices as it utilizes savings to substantially lower out-of-pocket prescription drug costs."

Go deeper

Rashida Tlaib warns of “corporate Dems” killing Biden bill

Rep. Rashida Tlaib speaks with Axios' Jonathan Swan. Photo: "Axios on HBO"

Rep. Rashida Tlaib (D-Mich.) told "Axios on HBO" she's "fearful" of what will happen to President Biden's big social spending bill in the Senate because "corporate Democrats" — including Sens. Joe Manchin (D-W.Va.) and Kyrsten Sinema (D-Ariz.) — are serving special interests.

Driving the news: "I know that they've been influenced and guided by folks that don't have the best interests of the American people in mind," the Squad member said.

Axios AM Deep Dive: Pandemic eating

Illustration: Sarah Grillo/Axios

A food revolution began pre-pandemic and COVID has only accelerated that. See how America's food industry is transforming, from farm to your table.

Abrams’ campaign manager rules out 2024 run if she wins governor's race

Photo: Jessica McGowan/Getty Images

In her first major interview since the official announcement, Stacey Abrams' campaign manager Lauren Groh-Wargo quashed speculation that the Georgia Democrat would interrupt a theoretical gubernatorial term to run for president in 2024.

Why it matters: Abrams' name has come up repeatedly as a top 2024 Democratic contender given President Joe Biden's age and Vice President Kamala Harris's low favorability rating.